Clinical Trial Update: Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis [Phase 2, Phase 3]

View source ↗

Summary

A multi-agent trial in pediatric and young adult patients explores preventing graft-versus-host disease after transplantation using post-transplant cyclophospha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Mixed Phenotype Acute Leukemia
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Abatacept (abatacept)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Ruxolitinib (ruxolitinib)
• Vedolizumab (vedolizumab)

Snippet

Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Conditions: Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2, Phase 3 | Status: RECRUITING